MatOrtho has received the CE mark for its ReCerf Hip Resurfacing Arthroplasty (HRA) device, confirming compliance with European safety and performance standards.
The approval broadens access to hip resurfacing across Europe and the UK, along with other parts of the world, where CE marking supports market entry.
ReCerf is the first ceramic hip resurfacing device available commercially, initially approved by Australia’s Therapeutic Goods Administration in November last year, said the company.
Constructed from BIOLOX delta ceramic, ReCerf addresses concerns linked to metal-on-metal bearings while preserving more of the patient’s natural bone.
The device offers surgeons a familiar procedure enhanced by advanced materials, supported by MatOrtho’s expertise in hip resurfacing.
Since its initial application in 2018, over 1,600 patients have benefited from the device, reporting positive outcomes and maintaining a low revision rate for up to six years.
With the CE mark, MatOrtho emphasises responsible adoption of ReCerf, and supports structured education, careful patient selection, and ongoing clinical monitoring.
The company announced a peer-led surgeon training programme to ensure the device’s safe and effective use.
The approval strengthens MatOrtho’s strategic growth and supports developing orthopaedic solutions for restoring joint function and enabling high-level activity.
MatOrtho founder Mike Tuke said: “This is more than a regulatory milestone. It represents two decades of focused effort to improve hip resurfacing through an advanced material.
“That became a possibility with BIOLOX delta and cooperation with CeramTec AG, which led in stages to ReCerf, an all-ceramic resurfacing implant that is already delivering excellent results.
“We’re proud to make this more widely available to specialist hip resurfacing surgeons and patients who want to stay active.”
